publication date: Dec. 22, 2016

Lung Cancer Tagrisso Shows Superiority vs. Chemo in EGFR T790M Mutation-Positive Disease

Data from phase III trial showed that Tagrisso (osimertinib) second-line therapy improved progression-free survival by 5.7 months, compared with standard platinum-based doublet chemotherapy (Hazard Ratio [HR]=0.3).

Tagrisso is sponsored by AstraZeneca.

The results from the trial, called AURA3, were presented at the 17th International Association for the Study of Lung Cancer World Conference on Lung Cancer in Vienna and published simultaneously online in The New England Journal of Medicine.

AURA3 data showed Tagrisso offered a statistically-significant improvement in PFS versus standard platinum-based doublet chemotherapy (10.1 months vs 4.4 months, hazard ratio [HR] 0.30; 95% confidence interval (CI):0.23, 0.41; p<0.001). In the 34 per cent of patients with central nervous system metastases at baseline, PFS was also significantly greater with Tagrisso than with platinum-based doublet chemotherapy (8.5 months vs 4.2 months, HR 0.32; 95% CI: 0.21, 0.49).

The AURA3 safety data for Tagrisso were in line with previous experience, the company said. Grade ≥3 drug-related adverse events were reported in 6 per cent of patients (n=16) treated with Tagrisso and 34 per cent (n=46) treated with platinum-based doublet chemotherapy. The most common drug-related AEs in the Tagrisso group, were diarrhea (29% overall; 1% Grade ≥3) and rash (28% overall; <1% Grade ≥3) and, in the chemotherapy group, they were nausea (47% … Continue reading CCL Dec 2016 – Tagrisso Shows Superiority vs. Chemo in EGFR T790M Mutation-Positive Disease

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.